

S-5 [12:20-13:00]

Beta-amyloid peptide degradation by aminopeptidase and its functional role in Alzheimer's disease pathogenesis

Dr. Sang Mee Ahn Jo
(*National Institute of Health*)

[12:20 – 13:00]

Beta-amyloid peptide degradation by aminopeptidase and its functional role in Alzheimer's disease pathogenesis

Sangmee Ahn Jo

**Division of Brain Diseases, Center for Biomedical Sciences
National Institute of Health, Korea**

Beta-amyloid peptide ($A\beta$) is a major component of senile plaques and its aggregation is considered to play a critical role in pathogenesis of Alzheimer's disease (AD). Aggregation of $A\beta$ could result from both increased synthesis and decreased degradation of $A\beta$. Our laboratory is interested in understanding the mechanism of $A\beta$ degradation in brain. Recently our laboratory identified a bacterial gene (SKAP) from *Streptomyces sp* KK565 whose protein product has an activity to cleave $A\beta$ and thus reduce the $A\beta$ -induced neurotoxicity. The sequence analysis showed that this gene was closely related to aminopeptidase. Maldi-Tof analysis showed that the recombinant SKAP protein expressed in *E. coli* cleaves both $A\beta$ 40 and $A\beta$ 42 at the N-terminal of $A\beta$ while an aminopeptidase from *Streptomyces griseus* (SGAP) cleaves at the C-terminal. We also identified a mammalian homolog of SKAP and the recombinant mammalian protein expressed in Sf-9 insect cells showed a similar proteolytic activity to SGAP, cutting $A\beta$ at the C-terminus. I will discuss the detailed mechanism of the enzyme action and its functional implication in AD.




Beta-amyloid peptide degradation by aminopeptidase and its functional role in Alzheimer's disease pathogenesis

Sangmee Ahn, Ph.D

Division of Brain Diseases
Center for Biomedical Sciences
and Biomedical Brain Research Center
National Institute of Health

2

Alzheimer's Disease (AD)



- ❑ **Pathology** : senile plaque (β -amyloid peptide), neurofibrillary tangle (τ), neocortical atrophy, neuron and synapse loss
- ❑ **Risk factors** : 1) increased age 2) family history
 3) gender 4) head injury
- ❑ **Genes involved in AD:**
 - 1) **Causative genes:** amyloid precursor protein (APP)
 presenilin 1, 2 (PS1, PS2)
 - 2) **Risk factor genes:** ApoE₄, alpha₂-macroglobulin (α_2 M), LRP

2005.12.3

Genes linked to AD

Table 1. Overview of Established AD Genes Influencing the A β Life Cycle

Gene (Location [Mb]) ^a	Genetic Mechanism	Biochemical Phenotype
<i>APOE</i> (19q13 [50 Mb])	LOAD: risk association ($\epsilon 4$ -allele)	a) \uparrow A β aggregation b) \downarrow A β clearance
<i>APP</i> (21q21 [28 Mb])	EOFAD: AA-change ($n = 16$ mutations ^b) LOAD: mostly neg. association findings	a) \uparrow A β_{42} /A β_{40} ratio b) \uparrow A β generation/A β aggregation
<i>PSEN1</i> (14q24 [73 Mb])	EOFAD: AA-change ($n = 140$ mutations ^b) LOAD: pos./neg. association findings	\uparrow A β_{42} /A β_{40} ratio
<i>PSEN2</i> (14q42 [223 Mb])	EOFAD: AA-change ($n = 10$ mutations ^b) LOAD: mostly neg. association findings	\uparrow A β_{42} /A β_{40} ratio

^a"Mb" = million base-pairs, "EOFAD" = early-onset familial AD, "LOAD" = late-onset AD.


^bLocation according to "UCSC Human Genome Browser," May 2004 assembly (URL: <http://genome.ucsc.edu/cgi-bin/hgGateway>).

^cAccording to the "Alzheimer's Disease Mutation Database" (URL: <http://molgen-www.uia.ac.be/ADMutations/>).

CELL 120:545-555 (2005)


2005.12.3

Amyloid precursor protein (APP) processing



2005.12.3

Amyloid peptide metabolism



2005.12.3

Proteolytic enzymes involved in degradation of the Alzheimer's amyloid peptide

Neprilysin family


- neprilysin (NEP)
- endothelin-converting enzyme (ECE-1)
- angiotensin-converting enzyme (ACE)

Insulin-degrading enzyme family

- insulin-degrading enzyme (IDE)


2005.12.3

Peptidases responsible for Aβ cleavage




2005.12.3

Metabolic Regulation of Brain Aβ by Neprilysin



Saigo group., Science(2001) 292:1550-1552





Screening of microbial secretion product


- ❑ *Identification of the candidate compounds from microbacteria, fungi and seaweeds libraries that are able to block Aβ-aggregation*

Amyloid peptide aggregation assay


1. Congo red Assay
 $Cb[M] = (A_{540}/25.295) - (A_{480}/46.306)$
2. Thioflavin T assay
3. Observe the pallet formation following centrifugation




Purification steps



Amino acid sequence comparison with other proteases




**Preparation of the recombinant protein, SKAP30kDa, and
identification with anti-SKAP antibody**




2005.12.3

Amyloid peptide_{40, 42} cleavage by SKAP: Maldi-Tof analysis

(A) $A\beta_{40}$ + SKAP, 3 h incubation




(B) $A\beta_{42}$ + SKAP, 3 h incubation



100 μ M of $A\beta$; 0.05 μ M SGAP

2005.12.3


Amyloid peptide_{40,42} cleavage by SGAP



100 μM of Aβ : 0.05 μM SGAP

2005.12.3

Inhibition of Aβ-induced neurotoxicity by SKAP



2005.12.3

Summary


- ❑ We purified and cloned a gene (SKAP) from *Streptomyces* sp. (#90565) whose product is able to cleave amyloid peptide.
Coding region=1314 bp, 437 amino acid, M.W.=45,209
- ❑ Recombinant SKAP protein (30 kDa) blocked both fibrillation of amyloid peptide and reduced amyloid peptide-induced neuronal toxicity.

2005.12.3

Peptidase X


- ❑ 90-100 kDa transmembrane protein
- ❑ Located on neuronal and glial surfaces
- ❑ Tissue specificity: in various tissues

Schematic domain structure of human peptidase X




2005.12.3


Preparation of recombinant peptidase G and measurement of its activity



A β_{40} degradation by peptidaseX, NEP, IDE: Transient transfection




$A\beta_{40-1}$ and $A\beta_{1-18}$ are not cleaved by peptidase G.




2005.12.3

$A\beta_{40}$ aggregation is reduced by recombinant peptidaseG protein



2005.12.3

Neuronal cell death induced by A β ₄₀ decreased by incubation with peptidase G



2005.12.3

Summary

- Both synthetic and endogenous A β are degraded by peptidase G.
- Both A β ₄₀ and 42 are cleaved by peptidase G.
- Peptidase G cleaves A β ₄₀ into small fragments (A β ₁₈) which lacks aggregation property and are not toxic to neuron.
- Peptidase G seems to degrade multimeric A β more efficiently than monomeric A β .
- Peptidase G protects neurons from toxicity induced by A β by cleaving it into smaller fragments.
- Thus, dis-regulation of peptidase G could contribute amyloid deposit found in AD brain.

2005.12.3

**Ongoing project with aminopeptidase G and its future
application to AD therapy**

- Treatment of AD mouse model (APP and presenilin) with peptidase G inhibitor: increases the both Ab40 and 42 level.
- Gene delivery of peptidaseG into the brain of AD model mouse
- Identification of the pharmacological agents that increase the endogenous peptidaseG activity
- Identification of the transcriptional factors or the signaling pathways that stimulate transcription of the peptidaseG gene

2005.12.3

**Div. of Brain Diseases, NIH, Korea
Sangmee Ahn, Ph.D**

SKAP:

Yoo Chul Bae, MS
Park Jeong Eun, Ph.D

PeptidaseG:

Kim, MinJu, MD, PhD
Ahn, Kyungsook, Ph.D
Soyoung Suh, Ph.D
Chae Sansook, BS
Jang Bong Kum, MS
Hyuck Kim, MS
Chulman Jo, Ph.D

**Center for Biomedical Sciences,
NIH, Korea
Inho Jo, Ph.D**

Shin-Hyun Joo, MS
Kim Eun Kyung, MS

Thank you!!

Samsung Medical Center

Kim Doh Kwan, MD, PhD

**Ansan Korea University
Dept. of psychiatry**

Han Chang Soo, MD, PhD

2005.12.3

Abstract for Symposium

II. Strategy for New Drug Development [14:00-17:10]